Our mission is to simplify and democratize the treatment of lung disease, using biotechnology to design therapies for PAH and other fatal lung diseases.

Synthetic Genomics is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V.The Mammalian Synthetic Biology group at SGI is a cross-disciplinary R&D team utilizing cutting-edge sequencing and bioinformatics, and cellular and molecular biology technologies for large-scale genome engineering of mammalian cells. The proprietary technologies developed at SGI for DNA design and synthesis, and genome engineering enable the rapid and efficient modification of mammalian genomes to address critical unmet needs in the fields of medicine, pharmaceuticals and biotechnology.

Ablexis, LLC is a biotechnology company dedicated to developing the AlivaMab Mouse technology, an innovative, next-generation platform for antibody drug discovery based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc. The AlivaMab Mouse platform will provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies to treat human diseases. Ablexis intends to commercialize the AlivaMab Mouse platform through creative partnering strategies.

• Research and development of antibody therapeutics directed against immunological targets for the treatment of disease• Identification and investigation of strategic alliances with corporate and academic partners• Design and creation of large-scale modifications of the mouse genome; co-creator of the VelocImmune mouse for production of fully-human antibodies• Project coordinator-Gates Grand Challenges in Global Health; production of novel mouse models for the testing of human vaccines in collaboration with Dr. Richard Flavell (Yale) and Dr. Markus Manz (IRB Bellinzona)• Collaboration coordinator; organize and oversee collaborations with academic laboratories